169 related articles for article (PubMed ID: 36070052)
1. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
Luo Y; Yang YC; Ma B; Xu WB; Liao T; Wang Y
Endocrine; 2022 Dec; 78(3):517-530. PubMed ID: 36070052
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms.
Li C; Dong X; Yuan Q; Xu G; Di Z; Yang Y; Hou J; Zheng L; Chen W; Wu G
J Endocrinol Invest; 2023 Aug; 46(8):1633-1650. PubMed ID: 36725810
[TBL] [Abstract][Full Text] [Related]
3. IL2RA
Pan Z; Bao L; Lu X; Hu X; Li L; Chen J; Jin T; Zhang Y; Tan Z; Huang P; Ge M
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166591. PubMed ID: 36328145
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
5. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer.
Feng C; Tao Y; Yu C; Wang L; Liu X; Cao Y
Cancer Gene Ther; 2023 Dec; 30(12):1598-1609. PubMed ID: 37679527
[TBL] [Abstract][Full Text] [Related]
6. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
Ma Y; Cang S; Li G; Su Y; Zhang H; Wang L; Yang J; Shi X; Qin G; Yuan H
J Cell Physiol; 2019 Dec; 234(12):22260-22271. PubMed ID: 31081124
[TBL] [Abstract][Full Text] [Related]
8. LINC00886 Negatively Regulates Malignancy in Anaplastic Thyroid Cancer.
Ma B; Luo Y; Xu W; Han L; Liu W; Liao T; Yang Y; Wang Y
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36726346
[TBL] [Abstract][Full Text] [Related]
9. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
10. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
[TBL] [Abstract][Full Text] [Related]
11. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
12. Identification of key pathways and biomarkers in anaplastic thyroid cancer using an integrated analysis.
Zhou J; Dong S; Shi C
J BUON; 2020; 25(6):2690-2699. PubMed ID: 33455115
[TBL] [Abstract][Full Text] [Related]
13. Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis.
Li L; Zhu M; Huang H; Wu J; Meng D
Technol Cancer Res Treat; 2020; 19():1533033820962135. PubMed ID: 33025856
[TBL] [Abstract][Full Text] [Related]
14. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.
Ng TSC; Gunda V; Li R; Prytyskach M; Iwamoto Y; Kohler RH; Parangi S; Weissleder R; Miller MA
Radiology; 2021 Jan; 298(1):123-132. PubMed ID: 33107799
[TBL] [Abstract][Full Text] [Related]
15. Identification of a six-gene prognostic signature for bladder cancer associated macrophage.
Jiang Y; Qu X; Zhang M; Zhang L; Yang T; Ma M; Jing M; Zhang N; Song R; Zhang Y; Yang Z; Zhang Y; Pu Y; Fan J
Front Immunol; 2022; 13():930352. PubMed ID: 36275756
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.
Yao J; Duan L; Huang X; Liu J; Fan X; Xiao Z; Yan R; Liu H; An G; Hu B; Ge Y
Front Oncol; 2021; 11():769727. PubMed ID: 34926275
[TBL] [Abstract][Full Text] [Related]
17. A signature of circadian rhythm genes in driving anaplastic thyroid carcinoma malignant progression.
Xu T; Jin T; Lu X; Pan Z; Tan Z; Zheng C; Liu Y; Hu X; Ba L; Ren H; Chen J; Zhu C; Ge M; Huang P
Cell Signal; 2022 Jul; 95():110332. PubMed ID: 35430345
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for anaplastic thyroid carcinoma: the present and future.
Lu X; Bao L; Pan Z; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912
[TBL] [Abstract][Full Text] [Related]
19. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
20. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
